Combinational Drug Therapy Based Mouth Dissolving Tablet of Valsartan and Olmesartan for the Effective Management of Hypertension

Abstract

This study aimed to develop and optimize orodispersible tablets (ODTs) containing a combination of Olmesartan and Valsartan, to improve the patient compliance and antihypertensive efficacy. The antihypertensive activity of both drugs in different combinations was determined by ACE inhibitory activity, and the result suggested a highly synergistic effect. Fifteen formulations were evaluated using a design of experiments approach, with Croscarmellose sodium, Microcrystalline cellulose and Thymol as independent variables affecting disintegration time, swelling index, and wetting time.

The optimized formulation (F8) showed rapid disintegration (14 seconds) and high drug release (>90%), with acceptable hardness (2.5 kg/cm²), friability (<1%), and thickness (3.5 mm). The tablets exhibited good flow properties, suitable for direct compression, and water absorption ratio ranged from 71.19% to 77.23%, indicating effective hydration and swelling properties. Stability experiments verified that F11 was physically and chemically stable for 90 days at different storage temperatures (25°C/60% RH and 40°C/75% RH).

 These findings suggest that the developed ODTs have potential as a novel formulation approach for managing hypertension, offering improved patient compliance, therapeutic outcomes, and convenience.